Related Experiment Videos
Treating periodontal diseases by blocking tissue-destructive enzymes
L M Golub1, M Wolff, S Roberts
1Department of Oral Biology and Pathology, School of Dental Medicine, SUNY at Stony Brook 11794-8700.
Journal of the American Dental Association (1939)
|February 1, 1994
Summary
Tetracyclines, unlike other antibiotics, inhibit enzymes that degrade collagen. This discovery offers a novel therapeutic strategy for periodontal diseases and other medical conditions, independent of their antibiotic properties.
Area of Science:
- Pharmacology
- Biochemistry
- Periodontology
Background:
- Collagen degradation contributes to various diseases, including periodontal disease.
- Existing treatments may not effectively target collagen-destructive enzymes.
- Tetracyclines are known for their antimicrobial properties.
Purpose of the Study:
- To investigate the non-antimicrobial effects of tetracyclines.
- To explore the potential of tetracyclines in inhibiting host-derived collagen-destructive enzymes.
- To establish a new therapeutic approach for collagen-related disorders.
Main Methods:
- The study focused on the "Stony Brook group" discovery.
- Comparative analysis of tetracyclines versus other antibiotics.
- Evaluation of enzyme inhibition unrelated to antimicrobial activity.
Main Results:
- Tetracyclines demonstrated the ability to inhibit host-derived collagen-destructive enzymes.
- This inhibitory effect was distinct from the antimicrobial activity of tetracyclines.
- Other antibiotics did not exhibit this collagen-enzyme inhibitory property.
Conclusions:
- Tetracyclines possess a novel property to inhibit collagen-destructive enzymes.
- This finding presents a new therapeutic avenue for periodontal diseases.
- The discovery holds potential for treating a range of medical disorders involving collagen degradation.